GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » T2 Biosystems Inc (NAS:TTOO) » Definitions » Cyclically Adjusted Price-to-FCF

T2 Biosystems (T2 Biosystems) Cyclically Adjusted Price-to-FCF : (As of May. 18, 2024)


View and export this data going back to 2014. Start your Free Trial

What is T2 Biosystems Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


T2 Biosystems Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for T2 Biosystems's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

T2 Biosystems Cyclically Adjusted Price-to-FCF Chart

T2 Biosystems Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

T2 Biosystems Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of T2 Biosystems's Cyclically Adjusted Price-to-FCF

For the Diagnostics & Research subindustry, T2 Biosystems's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


T2 Biosystems's Cyclically Adjusted Price-to-FCF Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, T2 Biosystems's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where T2 Biosystems's Cyclically Adjusted Price-to-FCF falls into.



T2 Biosystems Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

T2 Biosystems's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, T2 Biosystems's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-2.293/131.7762*131.7762
=-2.293

Current CPI (Mar. 2024) = 131.7762.

T2 Biosystems Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 -36.917 100.560 -48.377
201409 -64.831 100.428 -85.068
201412 -47.650 99.070 -63.381
201503 -44.050 99.621 -58.268
201506 -62.670 100.684 -82.023
201509 -64.872 100.392 -85.152
201512 -50.207 99.792 -66.299
201603 -57.826 100.470 -75.844
201606 -57.473 101.688 -74.478
201609 -51.108 101.861 -66.118
201612 -36.695 101.863 -47.471
201703 -47.056 102.862 -60.283
201706 -42.655 103.349 -54.388
201709 -37.564 104.136 -47.535
201712 -30.507 104.011 -38.651
201803 -32.772 105.290 -41.016
201806 -23.909 106.317 -29.634
201809 -23.847 106.507 -29.505
201812 -21.159 105.998 -26.305
201903 -29.483 107.251 -36.225
201906 -20.473 108.070 -24.964
201909 -30.454 108.329 -37.045
201912 -21.180 108.420 -25.743
202003 -21.585 108.902 -26.119
202006 -11.264 108.767 -13.647
202009 -4.419 109.815 -5.303
202012 -6.164 109.897 -7.391
202103 -6.009 111.754 -7.086
202106 -6.910 114.631 -7.943
202109 -5.838 115.734 -6.647
202112 -6.034 117.630 -6.760
202203 -425.588 121.301 -462.341
202206 -288.686 125.017 -304.295
202209 -267.150 125.227 -281.123
202212 -140.068 125.222 -147.399
202303 -96.029 127.348 -99.368
202306 -15.352 128.729 -15.715
202309 -2.994 129.860 -3.038
202312 -2.327 129.419 -2.369
202403 -2.293 131.776 -2.293

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


T2 Biosystems  (NAS:TTOO) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


T2 Biosystems Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of T2 Biosystems's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


T2 Biosystems (T2 Biosystems) Business Description

Traded in Other Exchanges
Address
101 Hartwell Avenue, Lexington, MA, USA, 02421
T2 Biosystems Inc provides rapid in vitro diagnostic tests to hospitals and laboratories. The company's core technology is T2 Magnetic Resonance (T2MR) technology, which can detect a variety of molecular targets directly from whole blood. T2MR technology enables the T2Dx system, which is fully automated from patient sample to result for its panels focused on bacterial and fungal infections that could cause sepsis, and its pipeline panel for Lyme disease.
Executives
Cr Group L.p. 10 percent owner 1000 MAIN STREET, SUITE 2500, HOUSTON TX 77002
Crg Partners Iii - Parallel Fund (a) L.p. 10 percent owner C/O CAPITAL ROYALTY L.P., 1000 MAIN STREET, SUITE 2500, HOUSTON TX 77002
Crg Partners Iii L.p. 10 percent owner 1000 MAIN STREET, SUITE 2500, HOUSTON TX 77002
Crg Partners Iii - Parallel Fund B (cayman) L.p. 10 percent owner 1000 MAIN STREET, SUITE 2500, HOUSTON TX 77002
Crg Partners Iii (cayman) Lev Aiv I L.p. 10 percent owner 1000 MAIN STREET, SUITE 2500, HOUSTON TX 77002
Crg Partners Iii (cayman) Unlev Aiv I L.p. 10 percent owner 1000 MAIN STREET, SUITE 2500, HOUSTON TX 77002
Michael Terrence Gibbs officer: General Counsel 12 STONEY BROOK RD., HOPKINTON MA 01748
John M Sprague officer: Chief Financial Officer 101 HARTWELL AVE., LEXINGTON MA 02421
Sperzel John J Iii director, officer: See Remarks 61 CRESTVIEW LANE, BRUNSWICK ME 04011
Brett A. Giffin officer: Chief Commercial Officer 101 HARTWELL AVE., LEXINGTON MA 02421
Alec Barclay officer: SVP, Operations 101 HARTWELL AVE., LEXINGTON MA 02421
Aparna Ahuja officer: Chief Medical Officer 101 HARTWELL AVENUE, LEXINGTON MA 02421
Laura Lee Adams director 101 HARTWELL AVE., LEXINGTON MA 02421
Anthony Pare officer: Chief Commercial Officer HAEMONETICS CORPORATION, 400 WOOD ROAD, BRAINTREE MA 02184
Thierry Bernard director 101 HARTWELL AVENUE, LEXINGTON MA 02421